文献速递免疫规划

婴儿同时接种全液体即用型DTaP-IPV-HB-PRP-T六价疫苗与C群脑膜炎球菌结合疫苗

Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.
PubMed 文献 · Vaccine · 2016-12-09

在芬兰开展的一项III期开放标签随机多中心研究中,350名46-74日龄健康婴儿按1:1随机分为两组,分别在2、3、4月龄接种DTaP-IPV-HB-PRP-T疫苗,其中一组在2和4月龄同时接种MenC疫苗。结果显示,同时接种组第三剂后抗-HBs浓度≥10mIU/mL的比例为97.5%,未同时接种组为96.1%;同时接种组第二剂MenC后抗-MenC SBA滴度≥8的比例为100%。两个主要目标均达成,同时接种未影响各自免疫应答,所有疫苗耐受良好。

要点

  • 同时接种组第三剂DTaP-IPV-HB-PRP-T后抗-HBs≥10mIU/mL比例为97.5%,未同时接种组为96.1%。
  • 同时接种组第二剂MenC后抗-MenC SBA滴度≥8的比例为100%。
  • 同时接种DTaP-IPV-HB-PRP-T与MenC疫苗未影响各自抗原的免疫应答,所有疫苗耐受良好。

核心结论

  • 同时接种DTaP-IPV-HB-PRP-T与MenC疫苗未影响对两种疫苗各自抗原的免疫应答,所有疫苗耐受良好,两组DTaP-IPV-HB-PRP-T疫苗的安全性特征相似。

研究设计与样本

  • III期、开放标签、随机、多中心研究,在芬兰开展,纳入46-74日龄健康婴儿350名,按1:1随机分为同时接种MenC组(Group 1,n=175)和未接种MenC组(Group 2,n=175)。
  • 所有婴儿均在2、3、4月龄接种DTaP-IPV-HB-PRP-T疫苗,同时接种组在2和4月龄同时接种MenC疫苗,所有婴儿还接种常规轮状病毒疫苗和13价肺炎球菌结合疫苗。

主要发现

  • 第三剂DTaP-IPV-HB-PRP-T后一个月,抗-HBs浓度≥10mIU/mL的比例在同时接种组为97.5%[95%CI:93.1-99.3],未接种MenC组为96.1%[95%CI:91.8-98.6]。
  • 第二剂MenC后一个月,同时接种组抗-MenC SBA滴度≥8的比例为100%。
  • 两个主要目标均达成,次要免疫原性和安全性分析显示同时接种未影响对两种疫苗各自抗原的免疫应答,所有疫苗耐受良好,两组DTaP-IPV-HB-PRP-T疫苗安全性特征相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DTaP-IPV-HB-PRP-T or hexavalent vaccines are indicated for primary and booster vaccination of infants and toddlers against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib). The present study evaluates the safety and immunogenicity of a ready-to-use hexavalent vaccine when co-administered with a meningococcal serogroup C conjugate (MenC) vaccine in infants. This was a phase III, open-label, randomised, multicentre study conducted in Finland. Healthy infants, aged 46-74days (n=350), were randomised in a ratio of 1:1 to receive DTaP-IPV-HB-PRP-T vaccine at two, three and four months, either with a MenC vaccine co-administered at two and four months (Group 1; n=175) or without MenC vaccine (Group 2; n=175). All infants also received routine rotavirus and 13-valent pneumococcal conjugate vaccines. The proportion of participants with an anti-HBs concentration ⩾10mIU/mL assessed one month after the third dose of DTaP-IPV-HB-PRP-T vaccine was 97.5% [95%CI: 93.1-99.3] in the coadministration group and 96.1% [95%CI: 91.8-98.6] in the group without MenC vaccine. The proportion of participants with an anti-MenC SBA titre ⩾8 assessed one month after the second dose of MenC vaccine was 100% in the coadministration group. Both primary objectives were achieved. Secondary immunogenicity and safety analyses showed that co-administration of DTaP-IPV-HB-PRP-T and MenC vaccines did not impact the immune response to the antigens of each of the two vaccines. All vaccines were well tolerated and the safety profile of DTaP-IPV-HB-PRP-T vaccine was similar in both groups. ClinicalTrials.gov identifier: NCT01839175; EudraCT number: 2012-005547-24.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vesikari T, Borrow R, Da Costa X, et al. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vaccine. 2016. PMID: 27939054. doi:10.1016/j.vaccine.2016.11.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。